The Joint

16th International Child Neurology Congress


49th Annual Child Neurology Society Meeting


  • Register by December 31, 2020 for unlimited access thru March 31, 2021:

    • 62 sessions (worth more than 100 CME credits)
    • 600+ posters and platform sessions
    • 10-part American Creativity, Ingenuity & Diversity program
    • Sponsor & Exhibitor Microsites (access ends December 31, 2020)
    • IF YOU HAVE REGISTERED: Click here to go to site
    • IF YOU HAVE NOT REGISTERED: Click here to register by December 31

for their generous support
of the live/virtual meeting
and On Demand content
(click to see full listing & logos)


Helpful Resources:


The central hub for information about the Joint ICNA-CNS Virtual Meeting is hosted by ICNA:

Virtual Meeting Schedule at a Glance


ON DEMAND ACCESS: November 11 - March 31, 2021

  • If you have already registered for the meeting, you do not need to register again or change your registration in any way. Your registration gives you access to all On Demand content posted through March 31, 2021
  • Click the following URL:
  • On Demand Content will be available through March 31, 2021
  • All Posters and Platform Presentations are available On Demand
  • Special Programming in Networking Lounge/Happy Hour: "American Creativity, Ingenuity, and Diversity" is available On Demand: Please be sure to go to the Networking Lounge anytime to view 1 of 10 special programs put together by CNS President, Dr. Phillip Pearl, his colleague at Boston Children’s Hospital, Dr. David Urion, and world-class jazz musicians from the Berklee College of Music in Boston, MA.
  • CME may be earned for On Demand content (other than posters and platform presentations) not claimed for CME for live participation October 12-23. See CME CREDIT guidelines below.


Industry Sponsored Sessions available On Demand:

SMA Horizons: What Is in the Future for SMA Management?

In this recording of the virtual meeting presented at CNS on October 14, 2020, Dr. Claudia Chiriboga, Dr. Julie Parsons, and Dr. Perry Shieh discuss several patients they have seen and treated with spinal muscular atrophy (SMA). Follow a patient on their journey with diagnosis and management of SMA. Our expert panel engages in a roundtable discussion on the importance of early detection and treatment. The latest clinical trial data is also discussed.
On-Demand Page Link

Distinguishing Pediatric Movement Disorders: Uncovering AADC Deficiency

This satellite symposium was held live at the 2020 ICNA-CNS Virtual Meeting on October 14 and 19, 2020.
The symposium investigated how to differentiate pediatric neurological disorders that may resemble other conditions, with specific examples such as cerebral palsy, epilepsy, and select neurotransmitter disorders, including aromatic L-amino acid decarboxylase (AADC) deficiency. Experts shared their clinical experience with regard to the diagnosis of AADC deficiency in patients who initially presented with symptoms resembling other, more common pediatric movement disorders. Discussion included an overview of key clinical features, diagnostic tests, and screening methods for patients with suspected AADC deficiency and review of current management options as well as treatments in development.
PTC Therapeutics On-Demand Page

Expanding Possibilities in the Treatment of Spinal Muscular Atrophy Available On Demand

SMA is an inherited, degenerative neuromuscular disease that can result in severe muscle weakness and loss of function over time.

In this session, Dr. Perry Shieh of David Geffen School of Medicine at UCLA will present efficacy and safety data for an approved SMA treatment option, as well as case studies reflecting the real-world spectrum of patients with SMA.
Genentech On-Demand Page

Progressive Pathways: Recent Recommendations and Emerging Therapies for Treating NF1-Associated Tumors

Neurofibromatosis type 1 (NF1) is an incurable genetic disorder that primarily gives rise to nervous system tumors but can also lead to multisystem involvement. Neurofibromas are a key feature of NF1, and approximately 50% of patients will develop plexiform neurofibromas (PNs), which are associated with substantial morbidity and carry the potential to transform into malignant peripheral nerve sheath tumors. Optimal care of children with NF1 and NF1-related plexiform tumors includes awareness of the disease biology and the most recent clinical data on innovative therapies for managing the disease. This web broadcast features an expert review of treatment recommendations, current management paradigms, and challenges in the care of NF1 and NF1-associated tumors in children, as well as insight into the expanding landscape of targeted therapies and guidance on effectively incorporating these strategies into patient care.
Chair & Presenter
Roger J. Packer, MD
Gilbert Family Neurofibromatosis Institute
Brain Tumor Institute
Children’s National Hospital
The George Washington University Medical Center
Washington, DC

Michael J. Fisher, MD
The Children's Hospital of Philadelphia
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by an independent educational grant from AstraZeneca.

On-Demand Page Link